Almac Group, the global contract pharmaceutical development and manufacturing organization, is pleased to announce its participation in the Global Clinical Supply BlockChain working group (GCSBWG).Other Clinical Supply Blockchain Working Group members are from Pfizer, Merck, UCLA, Bracket, Thermo Fisher, Barry Moore, GlaxoSmithKline, Marken, and GS1.
With Phase 1 of the GSCWG complete, the group has published a whitepaper entitled “Transforming Pharmaceutical Clinical Supply Messaging with BlockChain”which outlines the program’s highlights to date. An iOS mobile application called “KitChain MVP” has also been built upon a hyperleger fabric permissioned BlockChain infrastructure. The ultimate aim of the working group is to envision a messaging and notification platform which can support the performance requirements of the whole clinical supply chain.
Almac’s Mark Hanly, Strategic Business Analysis Manager and Mark McColgan, Software Development Manager, will continue to work alongside a diverse group of global academia, pharmaceutical companies and other Contract Manufacturing Organisations through the next phases of the working group and contribute pertinent insight and debate. With this group there was significant potential to enhance the depth and breadth of knowledge on how BlockChain could potentially be applied in the industry.
Andrew Hillis, Vice President and Group Head of Information Services, Almac Group, commented, “The rapid adoption of BlockChain technology, coupled with its clear applicability to the clinical supply chain, make this project extremely timely and relevant to meeting the future challenges of our industry. We’re privileged to contribute our experiences and perspectives as one of the world’s largest global clinical supply providers to this endeavor that if successful, will undoubtedly have a major impact on clinical sites and ultimately, patients.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.